REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients
Back to Research Library

Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients

A new study initiated by Novo Nordisk A/S aims to evaluate how well patients adhere to and stay on their medication when using Ozempic (semaglutide) compared with other anti-diabetic drugs for treating type 2 diabetes mellitus (T2DM). This real-world research, listed under NCT07456774 on ClinicalTrials.gov, offers valuable insights into the effectiveness and patient compliance of semaglutide in managing T2DM in China.

Background

Type 2 diabetes is a chronic condition that affects millions of people worldwide. Effective management often involves long-term use of medications to control blood sugar levels and prevent complications such as heart attacks (MACE) and kidney damage. Semaglutide, the active ingredient in Ozempic, has shown promising results in clinical trials for improving glycemic control and reducing cardiovascular risks. However, there is a need to understand how patients respond to this treatment in real-world settings where adherence can be challenging.

The study's primary objective is to assess the incidence of major adverse cardiac events (MACE) and renal complications between Ozempic users and those on other anti-diabetic medications among adult T2DM patients. By comparing these outcomes, researchers hope to provide a clearer picture of semaglutide’s long-term benefits versus traditional treatments.

Key Details

This retrospective study is currently enrolling participants who have already been using either Ozempic or another form of antidiabetic medication. The research team will analyze medical records and patient data to track adherence rates, persistence with treatment, and health outcomes over time.

The inclusion criteria are broad, aiming to include a diverse group of T2DM patients across various age groups, genders, and ethnicities. This comprehensive approach is crucial for ensuring the study's findings can be generalized to different populations.

Novo Nordisk’s initiative underscores the growing importance of real-world evidence in evaluating drug efficacy and safety beyond what randomized controlled trials (RCTs) can provide. By focusing on adherence and persistence rates, this research addresses one of the critical challenges in diabetes management: patient compliance with prescribed treatments.

Key Takeaways

  • Comparative Analysis: The study will compare Ozempic users to those on other anti-diabetic drugs for better understanding of long-term benefits.
  • Patient Adherence: It aims to assess how well patients stick to their medication regimen over time, which is crucial for managing T2DM effectively.
  • Health Outcomes: Researchers will track major adverse cardiac events and renal complications as key indicators of treatment success.
  • Diverse Population: The study includes a wide range of patient demographics to ensure the results are applicable across different groups.

What This Means

For the peptide research community, this study highlights the importance of real-world evidence in evaluating new treatments like semaglutide. By understanding how patients interact with and benefit from these medications outside of controlled settings, researchers can provide more robust recommendations for clinical practice.

Moreover, the findings could influence future regulatory decisions by the FDA regarding peptide therapies. Demonstrating high adherence rates and positive health outcomes may lead to wider adoption of Ozempic in diabetes management protocols.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07456774) — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.